This study describes Ac-SDKP, the N-terminal tetrapeptide of thymosin beta-4 and a substrate of angiotensin-converting enzyme, as an orally available peptide. Ac-SDKP was given by mouth to two mouse models of diabetic kidney disease, alone and alongside an ACE inhibitor, and oral dosing raised measured urine Ac-SDKP levels, with the combination producing the highest levels. Measured fibrosis endpoints in kidney tissue were reduced in the orally dosed groups. The rise in urine levels after oral dosing is direct evidence the peptide was absorbed. This is animal model evidence and does not establish efficacy or safety in human populations.
For your business
Oral Ac-SDKP raised urine levels in diabetic mice, suggesting bioavailability and renal activity worth monitoring in peptide-curious patients.